On the first day of 2026, the biotechnology firm Enveric Biosciences announced the issuance of a new US patent for a series of innovative molecules designed to treat psychiatric and neurological conditions.
Innovation in molecular architecture US Patent No. 12,492,179 covers substituted ethylamine fused heterocyclic mescaline derivatives. These molecules are specifically engineered to harness neuroplastogenic properties—the ability to promote brain plasticity—without triggering hallucinogenic side effects. By targeting essential receptors through novel pathways, these compounds aim to provide superior efficacy and an improved safety profile compared to traditional neuropsychiatric therapies.
Strategic value and intellectual property strength Securing a composition-of-matter patent represents the most robust form of IP protection in the pharmaceutical industry. This milestone offers several strategic advantages:
-
Securing development pathways: It provides a stable framework for long-term clinical trials and ensures a viable return for investors.
-
Expanding partnership opportunities: The patent enhances the company’s leverage for licensing deals and collaborations with major pharmaceutical players focused on neuropsychiatric therapeutics.
-
Addressing unmet medical needs: The research targets patients suffering from neurological, neuropsychiatric, and addiction disorders who currently have limited treatment options.
Long-term vision Leveraging its unique drug discovery platform, Enveric continues to expand its library of patent-protected chemical structures. The company’s focus remains on chemically modifying known pharmacological compounds to create optimized therapies, positioning itself as a leader in the development of non-hallucinogenic small-molecule treatments for central nervous system disorders.
Source: https://vohnetwork.com/news/pharma/enveric-biosciences-granted-us-patent-for-innovative-mental-health-therapies